Posts

Sanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continue

on

Create Medicines raises $122M to advance in vivo CAR-T programs

on

Kyverna Therapeutics Advances Toward First CAR-T Approval in Autoimmune Diseases with Strong SPS Trial Data

on

Earendil Labs Raises $787M in AI Biotech Funding Amid Hong Kong IPO Considerations

on

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

on

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

on

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

on

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

on

RTW-backed startup Yarrow Bioscience signs autoimmune antibody deal with China’s GenSci

on

Biotech interest shifting from obesity ‘halo’ to other areas like oncology and blood cancers

on

Recent obesity and IL-6 program updates for Fractyl, Helicore, and Tiziana

on

Eli Lilly to Invest Over $1 Billion to Expand Manufacturing Footprint in India

on

Novartis antibody ianalumab clinches another Phase 3 win in rare blood disease (ITP)

on

Odyssey Therapeutics Abandons IPO Plans in Latest Sign of Tough Environment for Biotech Listings

on

Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology

on

Exclusive: Merida Biosciences gets $121M to treat autoimmune and allergy diseases at their roots

on